Request Demo
Last update 13 Dec 2025
Turenkibart
Last update 13 Dec 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms SCT650C |
Target |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 682570434L
Source: *****
Sequence Code 1035356743H
Source: *****
Related
6
Clinical Trials associated with TurenkibartNCT07244510
A Phase II, Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SCT650C in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06197009
A Randomized, Double-blinded, Phase II, Placebo-controlled Study to Evaluate the Safety and Efficacy of SCT650C in Participants With Axial Spondyloarthritis
NCT05894707
A Randomized, Double-blinded, Dose-escalation Phase Ia Study to Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
100 Clinical Results associated with Turenkibart
Login to view more data
100 Translational Medicine associated with Turenkibart
Login to view more data
100 Patents (Medical) associated with Turenkibart
Login to view more data
100 Deals associated with Turenkibart
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Plaque psoriasis | Phase 3 | China | 27 Nov 2025 | |
| Hidradenitis Suppurativa | Phase 2 | - | 18 Nov 2025 | |
| Rheumatoid Arthritis | Phase 2 | China | 14 Feb 2025 | |
| Axial Spondyloarthritis | Phase 2 | Turkey | 01 Jul 2024 | |
| Ankylosing Spondylitis | Phase 2 | Turkey | 27 May 2024 | |
| Autoimmune Diseases | Phase 1 | Australia | 01 Jun 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free